Skip to main content
Premium Trial:

Request an Annual Quote

Smart-Seq Aims to Improve on Methods for Single-Cell Transcriptomics


A new mRNA-seq method developed by researchers at the Karolinksa Institute in Stockholm and the Ludwig Cancer Institute, called Smart-Seq, can be used to study single-cell transcriptomics. Working in collaboration with Illumina, the researchers used the method to analyze gene expression in circulating tumor cells, though the Karolinska's Rickard Sandberg says it could be used to study a number of rare cell types.

"This method [makes it] possible for basically anyone to do single-cell transcriptome studies," Sandberg says. "That's to say, both medical or biological questions."

Current methods to examine single-cell transcriptomics suffer from limitations — one gives better measurements of the 3' end of transcripts while another better detects the 5' end. "The feature that we liked about Smart-Seq is that it has better full-length coverage across transcripts that can inform you, not only about the gene expression, but which variant of a gene is expressed," Sandberg says.

While many steps of the Smart-Seq protocol are similar to those of other approaches, it relies on template-switching technology, which Sandberg says allows it to generate full-length transcripts that can then be sequenced.

Using a series of RNA dilutions, Sandberg and his team determined that Smart-Seq generates results from 10-nanogram samples that are similar to results from standard mRNA-seq, and, with 1 nanogram of RNA, Smart-Seq results showed a small increase in variability as compared to the 10-nanogram samples. The team published its results in Nature Biotechnology in July.

As a further example, the researchers applied Smart-Seq to the analysis of gene expression of circulating tumor cells isolated from the blood of a melanoma patient. They report finding hundreds of differentially expressed genes from comparing a few cells per cell type. "We were hoping that the levels of variation would be low enough, that yes, you don't need to sequence 50 cells of each type in order to draw biological conclusions," Sandberg says. "In retrospect, we are happy that with a few cells we can see many, many significant differences — several hundreds of them."

This approach, he adds, could also be used to study cell heterogeneity in tumors or differences between normal cell types.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.